ERBB2 and breast cancer: INQAT activities, relating to the evaluation of the performance level of participant laboratories in IHC determination of HER2 in BC, initially focused its attention on evaluating the analytical phase (interpretation) of the biomarker [17], then gradually extended into the pre-analytical phase (tissue staining) [18].